Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
Recruiting now · Phase 1/Phase 2
Conditions studied: Neurogenic Detrusor Overactivity, Spinal Cord Injuries
In brief
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
Key facts
- Study ID
- NCT06596291
- Run by
- Cyllene Therapeutics
- People needed
- 16
- Starts
- 2025-01-08
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-02-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rancho Los Amigos National Rehabilitation Center — Downey, California, United States (enrolling)
- Sidney Kimmel Medical College — Philadelphia, Pennsylvania, United States (enrolling)
- UTHealth Houston / TIRR Memorial Hermann — Houston, Texas, United States (enrolling)
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.